1
HAYASHI Keishi, WATANABE Tsuneo, TOYAMA Koji, KAMON Junji, MINAMI Masataka, UNI Miyuki, NASU Mariko: [fr] COMPOSÉS HÉTÉROCYCLIQUES TRICYCLIQUES ET INHIBITEURS DE JAK, [en] TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS. HAYASHI Keishi, WATANABE Tsuneo, TOYAMA Koji, KAMON Junji, MINAMI Masataka, UNI Miyuki, NASU Mariko, NISSAN CHEMICAL, SENMYO Kenji, February 21, 2013: WO/2013/024895 (16 worldwide citation)

[en] Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (Ia): wherein the rings Aa and Ba, Xa, Ya, R1a, R2a, R3a, L1a, L2a, L3a and na are as defined in the description.


2

3
Kadowaki Takashi, Yamauchi Toshimasa, Nagai Ryozo, Kamon Junji: Adiponectin receptor and gene coding for the same. Toudai Tlo, Nissan Chem, May 10, 2007: JP2007-111050 (2 worldwide citation)

PROBLEM TO BE SOLVED: To provide a new protein having an adiponectin binding capacity and effective for isolating and identifying human and mouse adiponectin receptors; a method for screening a ligand, agonist or antagonist for adiponectin receptor by the use of the protein; and a screening kit ther ...


4
HAYASHI KEISHI , WATANABE TSUNEO , TOYAMA KOJI , KAMON JUNJI , MINAMI MASATAKA , UNI MIYUKI , NASU MARIKO : [de] TRICYCLISCHE HETEROCYCLISCHE VERBINDUNGEN UND JAK-INHIBITOREN, [en] TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS, [fr] COMPOSÉS HÉTÉROCYCLIQUES TRICYCLIQUES ET INHIBITEURS DE JAK. NISSAN CHEMICAL IND  , January 4, 2017: EP3112370-A1

[en] Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (I a ): wherein the rings A a and B a , X a , Y a , R 1a , R 2a , R 3a , L 1a , L 2a , L 3a and n a are as defined in ...


5

6
Kadowaki Takashi, Yamauchi Toshimasa, Kamon Junji, Waki Hironori, Nagai Ryozo, Kimura Satoshi, Tomita Motoo: Insulin resistance improving agents. Japan Science and Technology Agency, Kadowaki Takashi, Yamauchi Toshimasa, Kamon Junji, Waki Hironori, Nagai Ryozo, Kimura Satoshi, Tomita Motoo, THE PATENT CORPORATE BODY ARUGA PATENT OFFICE, August 7, 2003: WO/2003/063894

It is intended to provide insulin resistance improving agents which contain, as the active ingredient, the C−terminal side spherical region of adiponectin C, adiponectin or genes thereof. It is also intended to provide remedies for type 2 diabetes which contain, as the active ingredient, the C−termi ...


7

8
Kadowaki Takashi, Yamauchi Toshimasa, Nagai Ryozo, Kamon Junji: Adiponectin receptor and gene encoding the same. Toudai Tlo, Nissan Chem, March 22, 2007: JP2007-070360

PROBLEM TO BE SOLVED: To isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein.SOLUTION: A prote ...


9
Kadowaki Takashi, Yamauchi Toshimasa, Oike Yuichi, Kamon Junji, Waki Hironori, Nagai Ryozo, Kimura Satoru, Yamamura Kenichi: Model animal having resistance to obesity and/or diabetes mellitus. Japan Science &Amp Technology, October 7, 2003: JP2003-284454

PROBLEM TO BE SOLVED: To provide a model animal not only capable of elucidating the mechanism causing obesity and/or diabetes mellitus, but also enabling new development of prophylactic or therapeutic agent for obesity and/or diabetes mellitus.SOLUTION: The model animal having resistance to obesity ...


10
Kadowaki Takashi, Yamauchi Toshimasa, Kamon Junji: Amp activation protein kinase activator. Japan Science &Amp Technology, January 22, 2004: JP2004-016074

PROBLEM TO BE SOLVED: To obtain an AMPK activator in which 5'-AMP activation protein kinase (AMPK) activation has the same effect as motility of fatty acid combustion, etc., and which is useful as a therapeutic agent for obesity and type 2 diabetes.SOLUTION: The AMP activation protein kinase activat ...